ARCHIVES

June issue of Business & Regulatory Report included.

This article is from The Cancer Letter archive.

Vol. 30 No. 27 | July 2, 2004

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

Reinventing NCI: Prevention Program Lacks Leadership, Reorganization Needed, Advisory Group Says

June 20, 1997

NIH Seeking More Women, Minorities On Committees

November 9, 1979

New Treatment For Malignant Glioma, IL13-PE38, Tested In Early Clinical Trials

December 28, 2001

FDA Advisors OK Levamisole, Conditional New Tamoxifen Use

February 9, 1990

Budge Act Includes Language On Coverage Of Oral Cancer Drugs

August 13, 1993